Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11331870 | 0.88 | KDM4E (0.55) | HSD17B2ESR1LMNAALDH1A1TSHR | |
| SCHEMBL3964444 | 0.83 | CA1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7492169 | 0.81 | CA12 (0.54) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL2095896 | 0.81 | MEN1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL128776 | 0.80 | CA12 (0.53) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL3830003 | 0.80 | KMT2A (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL9658861 | 0.80 | CA12 (0.57) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL9676481 | 0.79 | CYP1A2 (0.47) | LMNACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3149483 | 0.79 | CA12 (0.51) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL971745 | 0.79 | CA12 (0.51) | HSD17B2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701685-B2 | Spiropyrrolidines as MDM2 inhibitors | HUDSON BIOPHARMA INC. (US) | 2017-07-11 | — | — | US | claimed |
| EP-3183255-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | Hudson Biopharma Inc. (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016028391-A9 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016028391-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-02-25 | — | — | WO | claimed |
| US-20150322076-A1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. | 2015-11-12 | — | — | US | claimed |
| EP-3183255-B1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-9701685-B2 | Spiropyrrolidines as MDM2 inhibitors | HUDSON BIOPHARMA INC. (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3183255-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | Hudson Biopharma Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016028391-A9 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016028391-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20150322076-A1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. | 2015-11-12 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322076-A1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | TP53, RB1, MDM2 | HSD17B2 2352/4885CA12 4420/4885CA1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.